Yifan Zhai
YOU?
Author Swipe
View article: Immunization with outer membrane vesicles drived Proteus mirabilis protects mice against bacteria-induced lethality
Immunization with outer membrane vesicles drived Proteus mirabilis protects mice against bacteria-induced lethality Open
Introduction Proteus mirabilis ( Pm ) has emerged as a significant and widespread opportunistic pathogen affecting both humans and animals, resulting in substantial economic losses within the agricultural sector. While most conventional an…
View article: Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial
Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial Open
View article: Relationship between Pan-immuno-inflammatory value and hospitalized all-cause mortality in ischemic stroke patients: a retrospective cohort study and predictive modeling
Relationship between Pan-immuno-inflammatory value and hospitalized all-cause mortality in ischemic stroke patients: a retrospective cohort study and predictive modeling Open
Background Systemic inflammation and immune response are major factors in the development and progression of ischemic stroke (IS). Numerous studies have shown how Pan-immuno-inflammatory value (PIV) affects the chance of dying from a serio…
View article: Exploration and Practice of Narrative Medical Education Localization from a Dual-Track Integration Perspective
Exploration and Practice of Narrative Medical Education Localization from a Dual-Track Integration Perspective Open
Narrative medicine education, as a vehicle for medical humanities practice, cultivates narrative competence, empathy, and reflective abilities in medical students, playing a pivotal role in improving doctor-patient relationships and health…
View article: Using baseline MRI radiomics to predict the tumor shrinkage patterns in HR-Positive, HER2-Negative Breast Cancer
Using baseline MRI radiomics to predict the tumor shrinkage patterns in HR-Positive, HER2-Negative Breast Cancer Open
Introduction This study aimed to develop and validate a predictive model for tumor shrinkage patterns in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Methods A retro…
View article: Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity?
Fertility-preserving treatment of endometrial cancer and endometrial atypical hyperplasia for patients with metabolic abnormalities: Challenge or opportunity? Open
Background: This study aims to evaluate the efficacy of a regimen that combines anti-estrogen therapy with treatments targeting glucose, lipid, and calcium metabolism in patients diagnosed with early-stage endometrial cancer (EC) and endom…
View article: Alteration of hair growth in mice by circulating exosomes from Xinji fine-wool and small-tailed Han sheep
Alteration of hair growth in mice by circulating exosomes from Xinji fine-wool and small-tailed Han sheep Open
Introduction Animal hair growth is an important research topic in the field of breeding. Hair growth is affected by circulating exosomes in the plasma, and sheep wool fiber thickness is altered by intravenous injection of miRNA mimics. Met…
View article: Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research
Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research Open
Once considered an incurable disease with a poor prognosis (median survival, 3–6 years), chronic myeloid leukemia (CML) is now managed with a diverse clinical armamentarium that includes BCR::ABL1 tyrosine kinase inhibitors (TKIs), which h…
View article: Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice
Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice Open
View article: Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
View article: Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Representativeness of study participants.
View article: Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Summary of BH3 profiling for PBMC samples collected at baseline.
View article: Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
View article: Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Purpose: This global phase 1 trial investigated the safety, efficacy, pharmacokinetics, and pharmacodynamics of lisaftoclax (APG-2575), a novel, orally active, potent selective BCL-2 inhibitor, in patients with relapsed or refractory chron…
View article: Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Summary of BH3 profiling for PBMC samples collected at baseline.
View article: Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Representativeness of study participants.
View article: Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers
Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers Open
Olverembatinib (HQP1351) is a BCR‐ABL1 tyrosine kinase inhibitor with promising clinical activity. It is approved in China for the treatment of patients with chronic myeloid leukemia harboring drug‐resistant mutations, such as T315I . In v…
View article: Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells
Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells Open
View article: Supplementary Data 1 from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Supplementary Data 1 from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors Open
Supplementary Tables S1-S3 and Supplementary Figures S1-S4
View article: Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors Open
Purpose:B-cell lymphoma-extra-large (BCL-xL) regulates apoptosis and is an attractive anticancer therapeutic target. However, BCL-xL inhibition also kills mature platelets, hampering clinical development. Using an innovative prodrug strate…
View article: Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors Open
Purpose:B-cell lymphoma-extra-large (BCL-xL) regulates apoptosis and is an attractive anticancer therapeutic target. However, BCL-xL inhibition also kills mature platelets, hampering clinical development. Using an innovative prodrug strate…
View article: Supplementary Data 1 from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors
Supplementary Data 1 from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors Open
Supplementary Tables S1-S3 and Supplementary Figures S1-S4
View article: 72P Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A multi-center, single-arm, phase II study
72P Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small cell lung cancer: A multi-center, single-arm, phase II study Open
The PACIFIC trial established consolidation therapy with durvalumab as the standard of care for patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) without progression after chemoradiotherapy (CRT), however, addit…
View article: 1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)
1973P Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST) Open
View article: 1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)
1317MO Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC) Open
View article: Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Summary of BH3 profiling for PBMC samples collected at baseline.
View article: Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
View article: Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
View article: Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Representativeness of study participants.
View article: Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial Open
Representativeness of study participants.